Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
hehe, i also printed it out and showed it to my colleagues and i live in germany ;)
hope we can use it someday... :)
is that .pdf new? i haven't noticed it before??
http://beta.uwink.com/uwink/uWink_menu.pdf
ups, i guess i have to check my email more often... got them :)
all good with eqbm iyo?
didn't you learn anything from the EQBM fiasco?
isn't it more than enuff???
i don't follow it anylonger, but caution is always a good thing
you never know how real these chinese companies really are ;)
maybe they don't do it because we know it before they do? ;)
yep, they could save even more money if they put an explanation of the german bankcruptcy filing in same NR...
as a shareholder i would want to know what happend to the german network that was pr'd some time ago!
yep, a real money maker :D
fingers crossed ;)
do we know the url of the website now?? and i mean not the advertising one from globetel...
ok than i missed your point... it's sometimes hard, if english isn't your first language, to understand all properly... :)
but nonetheless it isn't right how GTEM handles this situation, if germany isn't needed anymore you close it and try to sell the assets, you don't file for bankcruptcy imho...
If Germany isn't going to return on the investment, soon, they turn to what will.
HUH? in case you missed it... there is no germany anymore!
i don't care about germany, i care about how the company handles it... and i don't like it!
we all know it, the link was posted where you can see it!
http://www.insolvenzbekanntmachungen.de/
and i edited my last post, Sigwald Leder is his name, i misstyped it sorry!
yep, and now we know for a fact that Sigwald Leder filed for insolvency... and no word from globetel... sad!
yep, Meridian must be a real company... if it were a scam it would fly ;)
did rob said anything about how globetel is going to adress the german situation??
i find it kind of strange that they didn't say anything about it yet, at least we all thought GTEM had an operational network in germany?!
what news? there were NO news...
or do you mean the financials posted on yahoo??
that was just yahoo related...
looks to me that Ms. Hui = Skolnik and now he doesn't need this virtual girl for pumping this scam any longer :)
didn't you ask those questions before you put money into this pennystock??
yes, i brought some serious DD to this board...
i know :)
did you even read my post??
we heard the same about germany and the network there...
guess what, the german subsidiary of Globetel is bankcrupt did the company yet told that to the shareholders?
and YES the bankcruptcy filing in germany is not bogus it is real!
anyone asked bleckman about this lately? last time he was not aware of it!!!?
this company really should stop bulls****ing their investors IF it's for real...
so obvious than that they did it release only because of the latest funding round imho!
just a thought...
the website looks like if it was made by the same ppl that made the globetel.net and sanswire.net website, so they may have had it for month...
problem was the PR was written also at the same time and they just forgot to change OTC:BB to OTC when they took it out of the drawer for releasing it?
sounds plausible to me :)
it's yahoo related i bet, because of the delisting to pink sheets...
happens all the time that old filings appear there as news than
that's Jim Profit :)
bagholders? i have freebies with NNPP :)
i just tried to say that i find your conspiracy theory also funny... :)
hehe, yep i read most of his postings.. he can't be serious
clueless pumper with lots of spelling errors ;)
i also like round numbers ;)
i hope you will win because than i'll win also :)
eXegenics Inc.: New Company; New Technology
Wednesday April 18, 6:12 am ET
Anthony Payne submits: In this article we feature a small company which is being formed as a reverse stock merger; the shell company is publicly traded eXegenics Inc. . Acuity Pharmaceuticals and Froptix, both privately owned pharmaceutical companies developing treatments for eye diseases, will merge into the shell company. The combined company will be renamed Opko Corp. and will be based in Miami. Opko intends to apply to have its shares listed on the American Stock Exchange.
Acuity is developing an RNAi agent called Bevasiranib, which is in Phase II clinical trials as a potential treatment for wet age-related macular degeneration [AMD] and diabetic macular edema [DME] both of which can lead to blindness.
In September 2006 Acuity Pharmaceuticals announced positive results from its Phase II trial for Bevasiranib sodium. The study was a randomized, double-blinded trial that included three dose levels of Bevasiranib tested in 129 patients with wet AMD at 28 sites nationwide. The study focused on patients with serious disease, classic or active minimally classic AMD, including those patients who had failed previous treatments. There was no placebo arm. The drug is injected locally into the eye, which reduces the possibility of systemic toxicities from the drug. Local injection was shown to be very safe in the study, with all doses well tolerated and most adverse events mild and related to the administration procedure. There were no systemic adverse events observed, an important consideration in an agent targeting vascular endothelial growth factor [VEGF].
AMD is formed in the eye when blood vessels form at the back of the eye sometimes resulting in blindness. VEGF is the growth factor which produces the blood vessels. By inhibiting the growth of these vessels it has been found that diseases which require blood vessel formation such as cancer and abnormally produce these vessels locally like AMD can be treated effectively by inhibiting this factor. Avastin (NYSE: DNA - News) works by this mechanism (see below).
Unlike antibody VEGF antagonists (Avastin), which neutralize VEGF that has already been produced in the eye, Bevasiranib works by shutting down the genes that produce future VEGF. As a result, there is residual VEGF remaining in the eye during the first weeks of administration of Bevasiranib, which stops production of new VEGF but does not neutralize the residual VEGF that naturally dissipates over time. Accordingly, the impact of the drug's anti-VEGF activity becomes evident only after several weeks of therapy, after the existing VEGF dissipates. This results in a lag between starting Bevasiranib therapy and observing a therapeutic effect. This would indicate that the RNAi mechanism of Bevasiranib may also be effective in combination with Lucentis from DNA, the current monoclonal inhibitor of VEGF (see below) on the market.
Bevasiranib uses RNA interference (RNAi) to silence genes that promote the overgrowth of blood vessels that lead to vision loss in wet AMD. This shuts down the production of VEGF, which has been shown to be the central stimulus in the development of wet AMD. Bevasiranib is administered directly into the eye and does not affect the patient systemically, an important safety consideration. A Phase III clinical trial which will further examine efficacy parameters, as well as dosing and dose scheduling regimens is being planned.
The former CEO and chairman of Ivax, Dr. Phillip Frost, will become chairman and CEO of Opko. The Frost Group will provide Opko with a $12 million line of credit. Proceeds from it, along with the about $16 million of cash held by eXegenics, will fund the company's upcoming Phase-III study of Bevasiranib.
Investment Analysis:
The AMD as a therapeutic market is growing in interest, especially with the approval of the VEGF antagonist from Genentech (NYSE: DNA - News), Lucentis in mid 2006. Sales in 2006 were $380 million. The company mentioned in its recent 10K that Avastin, a VEGF inhibitor used for cancer, is also effective for this indication and is being prescribed off-label. Another marketed therapeutic is Macugen, which is a pegylated aptamer (tight binding oligonucleotide) and was developed by Eyetech and licensed to Pfizer; Eyetech was subsequently purchased by OSI Pharmaceuticals. One of the scientists at Eyetech has joined eXegenics (Opko). Sales in 2006 were $103 million.
OSI have announced that it is divesting the eye business including Macugen as it believes sales of Macugen will be severely affected by the launch of Lucentis and they will concentrate on cancer and other diseases. They are attempting to obtain full rights to Macugen from Pfizer to assist in the divestiture.
Management of the new company appears experienced with a number of past successes; they are confident that there are sufficient funds to develop the molecule through Phase III. Local eye administration of oligonucleotide therapeutics has been the only route of administration for these types of compounds which have been successful so far; Macugen mentioned above, an aptamer, and Vitravene from ISIS, an antisense oligonucleotide against CMV retinitis. Finally, valuation is reasonable at present for a company with a compound going into Phase III. Although the stock has moved significantly since November we still believe it is a good investment for investors willing to take inherent biotech investment risk. It is a Company worth watching in 2007.
http://biz.yahoo.com/seekingalpha/070418/32674_id.html?.v=1
somebody said that, yes...
The agreement states that TAO-Technologies, in cooperation with the University of Stuttgart, will design several next-generation airships intended for multiple uses. These unique and proprietary designs are specific to certain customer demands and are intended to complement the suite of near-space vehicles currently being developed and built by GlobeTel's wholly owned subsidiary, Sanswire Networks LLC.
http://findarticles.com/p/articles/mi_m0EIN/is_2005_Oct_12/ai_n15685804
looks to me that TAO never gave the Airchain aka SkyDragon away..
because it was kicked into PK and there is no communications from company.
perfect way to let this stock quietly die... don't you think?
Nutrition 21 Announces Formation of Scientific Advisory Board
Wednesday April 18, 9:00 am ET
PURCHASE, N.Y.--(BUSINESS WIRE)--Nutrition 21, Inc. (NASDAQ: NXXI - News), a leading developer and marketer of chromium-based, selenium-based and omega-3 fish oil-based nutritional supplements, today announced the formation of its Scientific Advisory Board that will provide guidance on research and future product development.
The members of the Scientific Advisory Board are Dr. Robert Golden, Dean of the School of Medicine and Public Health and Vice Chancellor for Medical Affairs at the University of Wisconsin; Dr. Louis Ignarro, 1998 recipient of the Nobel Prize in Physiology or Medicine, Distinguished Professor of Pharmacology in the Department of Molecular and Medical Pharmacology, UCLA School of Medicine; Dr. Francine Kaufman, former president of the American Diabetes Association, Director of the Comprehensive Childhood Diabetes Center and Head of the Center for Endocrinology, Diabetes and Metabolism at Children's Hospital Los Angeles; and Dr. Ron Krauss, Senior Scientist and Director of Atherosclerosis Research at the Children's Hospital Oakland Research Institute, Guest Senior Scientist at the Department of Genome Sciences at Lawrence Berkeley National Laboratory and Adjunct Professor, Department of Nutritional Sciences University of California, Berkeley.
"Each of these distinguished members represents expertise and leadership in their respective areas and we are honored to have them be a part of our Scientific Advisory Board," said Paul Intlekofer, president and CEO of Nutrition 21. "The formation of this board will help ensure that Nutrition 21 is at the forefront of new scientific advances. This is another milestone in our continued growth and development as company committed to providing quality products backed by research."
More information on the Scientific Advisory Board members can be found at: http://www.nutrition21.com/About/Scientific/default.aspx
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium picolinate-based, selenium and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds over 30 patents for nutrition products and uses. The company markets Chromax® chromium picolinate, which is the most-studied form of the essential mineral chromium. Chromax, a supplement for healthy and pre-diabetic people that promotes insulin health and helps improve blood sugar metabolism, cardiovascular disease, control cravings and fight weight gain, is now available through food, drug and mass retailers nationwide. Another chromium picolinate-based supplement developed and marketed by Nutrition 21 is Diachrome®, a proprietary, non-prescription, insulin sensitizer for people with type 2 diabetes. It is sold in select drug retailers nationwide. Nutrition 21 also markets Selenomax®, a high selenium yeast supplement that stimulates and protects the immune system by supporting antibody production and preventing free-radical damage.
Selenomax is available at CVS/pharmacy in all its 6,200 retail stores nationwide, including PharmaCare Specialty Pharmacy locations, and on www.cvs.com. The Company is the exclusive importer of Icelandic fish oils, including omega-3 fatty acids, which are manufactured to pharmaceutical standards and sold under the Iceland Health® brand. More information is available at http://www.nutrition21.com/.
Contact:
Nutrition 21, Inc.
Maryrose Lombardo, 914-701-4525
Source: Nutrition 21, Inc.
the strange thing with altvater is... he did it again and again and again...
from wiman to hotzone to globetel now trimax...